Alligator and ImmuRx will use their proprietary technology platforms to develop a cancer vaccine adjuvant

LUND, Sweden | February 12, 2008 | Alligator Bioscience and ImmuRx today announced that they have entered into a strategic collaboration. Alligator and ImmuRx will use their proprietary technology platforms to develop a cancer vaccine adjuvant.

About Alligator Bioscience AB

Alligator Bioscience discovers and develops early protein drug candidates. The method used is the company' own patented FIND® technology (Fragment Induced Diversity).
Established in 2001 in Lund, Sweden, the company currently has 23 employees.
Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical, diagnostic and biotech industry and created an internal pipeline of therapeutic drug candidates. The areas of indication on which Alligator is focused are inflammatory diseases and cancer.
Alligator Bioscience operates from the Ideon Science Park in Lund, Sweden.

For further general information please visit www.alligatorbioscience.com.

About ImmuRx Inc.

ImmuRx Inc. is a biopharmaceutical company developing an adjuvant platform that stimulates the immune system to fight a wide variety of cancers and chronic infections. ImmuRx has developed the leading intellectual property estate for combinations of stimulants that trigger both the innate and adaptive halves of the immune system, producing more powerful and safer treatments. ImmuRx is based in Lebanon, New Hampshire, USA.

For further general information please visit www.ImmuRx.com.

SOURCE: Alligator Bioscience

---